| Wang Feng,Pan Yongxiang,Ding Lixin,et al.Estimation of renal absorbed doses in the treatment of neuroendocrine tumors using 177Lu-DOTA-TATE[J].Chinese Journal of Radiological Medicine and Protection,2021,41(9):700-704 |
| Estimation of renal absorbed doses in the treatment of neuroendocrine tumors using 177Lu-DOTA-TATE |
| Received:February 04, 2021 |
| DOI：10.3760/cma.j.issn.0254-5098.2021.09.011 |
| KeyWords:177Lu DOTA-TATE Neuroendocrine tumors Absorbed dose SPECT |
| FundProject:国家自然科学基金（81871386） |
| Author Name | Affiliation | E-mail | | Wang Feng | Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing Quality Control and Improvement Center for Nuclear Medicine, Nuclear Medicine Department, Peking University Cancer Hospital & Institute, Beijing 100036, China | | | Pan Yongxiang | Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing Quality Control and Improvement Center for Nuclear Medicine, Nuclear Medicine Department, Peking University Cancer Hospital & Institute, Beijing 100036, China | | | Ding Lixin | Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing Quality Control and Improvement Center for Nuclear Medicine, Nuclear Medicine Department, Peking University Cancer Hospital & Institute, Beijing 100036, China | | | Zhu hua | Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing Quality Control and Improvement Center for Nuclear Medicine, Nuclear Medicine Department, Peking University Cancer Hospital & Institute, Beijing 100036, China | | | Yu jiangyuan | Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing Quality Control and Improvement Center for Nuclear Medicine, Nuclear Medicine Department, Peking University Cancer Hospital & Institute, Beijing 100036, China | yujiangyuan@aliyun.com | | Yang Zhi | Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Beijing Quality Control and Improvement Center for Nuclear Medicine, Nuclear Medicine Department, Peking University Cancer Hospital & Institute, Beijing 100036, China | |
|
| Hits: 3357 |
| Download times: 1359 |
| Abstract:: |
| Objective To estimate the renal absorbed dose in the treatment of neuroendocrine tumors using 177Lu-DOTA-TATE and to assess the radiation safety and guide the treatment. Methods The dosimetric calculations of patients treated with 177Lu-DOTA-TATE were carried out based on planar images of single photon emission computed tomography (SPECT). The regions of interest (ROIs) of the whole body and kidneys were delineated and converted into activity. Accordingly, the time-activity curves of the ROIs were obtained. The effective half-lives and cumulative activity of ROIs were calculated through the fitting of a single exponential equation of the ROIs. Then the absorbed doses were calculated based on the medical internal radiation dosimetry (MIRD) formalism. Results A total of 11 patients with neuroendocrine tumors received 18 cycles of treatments with 177Lu-DOTA-TATE. The effective half-lives of 177Lu-DOTA-TATE in the whole body and kidneys were 20.0-99.8 h and 38.2-75.2 h, respectively, with an average of (57.3 ±21.4) h and (53.1 ±12.5) h, respectively. The renal absorbed doses of 177Lu-DTA-TATE were 0.25-1.48 mGy/MBq, with an average of (0.90 ±0.31) mGy/MBq. The minimum and maximum renal absorbed doses in a single treatment cycle were 1.8 Gy and 9.6 Gy, respectively, while the maximum renal absorbed dose in multiple treatment cycles was 21.7 Gy. Conclusions The renal absorbed doses in the treatment of neuroendocrine tumors using 177Lu-DOTA-TATE were estimated. The result indicate that the renal absorbed doses were lower than the tolerable dose limits. This study is expected to guide the precise treatment of neuroendocrine tumors. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
